Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 17 1 2023 01 16 4 8 Farzad Mollahoseini Foomani Blood Transfusion Organization Research Center, Iranian Blood Transfusion Organization, Mashhad, Iran Mahammad Hadi Sadeghain Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Saeede Bagheri Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran Zahra Badiee Pediatrics Department, Doctor Sheikh Hospital, Mashhad University of Medical Sciences, Mashhad, Iran Reihane Bazargani Blood Transfusion Organization Research Center, Iranian Blood Transfusion Organization, Mashhad, Iran Zahra Aryanpour Blood Transfusion Organization Research Center, Iranian Blood Transfusion Organization, Mashhad, Iran Saeid Hallajian Blood Transfusion Organization Research Center, Iranian Blood Transfusion Organization, Mashhad, Iran Seyyede Fatemeh Shams Blood Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran 2020 10 31 2021 05 01 Background:  Thalassemia is an inherited disease with anemia and hemolysis. Blood transfusion is a routine treatment for thalassemia patients; alloimmunization is one of the complications of blood transfusion, which is very serious for these patients, especially girls and young women.    Materials and Methods:  Four hundred forty-six thalassemia patients were examined in this cross-sectional study. Demographic information of patients was extracted and recorded. The phenotype of ABO, Rh, and Kell antigens (tube method) with antisera from IMMUNDIANOSTICA Company (Germany) and the frequency of alloantibodies were determined. Results: 55.8% of the studied individuals were male and 44.2% were female. The mean age of the studied patients was 19.94±10.63.  The alloantibodies were detected in 7.5% of pack cell receivers. The most prevalent phenotype of the ABO system was the O blood group (37.4%), and the most abundant antigen of the Rh group was ‘e’, which was found in 99.8% of the studied population. The most frequently detected alloantibody was Anti K (38.2%); concerning kell phenotype, (K_k+) and (K+k+) were found in 99.3% and 0.7% of patients, respectively. The frequency of Anti-D, Anti-C, Anti-c, and Anti-E was 23.5%, 14.7%, 2.9%, and 14.7%, respectively. Conclusion: According to the results of this paper, finding the compatible pack cells in terms of Kell and Rh systems antigens in addition to the ABO blood group is recommended to decrease the rate of alloantibodies in thalassemia patients. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1453 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1453/957

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 17 1 2023 01 16 1 3 Ali Akbar Pourfathollah Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran Karim Shamsasenjan Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran Mahmoud Hadipour Dehshal Mehregan Pharmacy, Tehran, Iran 2022 08 22 2023 01 07 No Abstracts  No Abstracts  No Abstracts  https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1899 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1899/956

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 17 1 2023 01 16 56 62 Rachel Hicks Brookdale University Hospital Medical Center Mohammed Alsabri Brookdale University Hospital Medical Center Mario Peichev Brookdale University Hospital Medical Center Viswanathan Kusum Brookdale University Hospital Medical Center 2020 11 02 2021 05 10 Periorbital swelling is a clinical presentation with a broad differential and potentially deleterious consequences. Causes range from benign, including allergic reaction, to vision- and life-threatening, including orbital cellulitis and orbital infarction. The recent climate of SARS-CoV-2 has further complicated this differential, as the virus poses broad clinical presentations with new manifestations reported frequently. Rapid identification of the underlying etiology is crucial, as treatment approaches diverge greatly. Here, we report the case of an African American adolescent male with a history of homozygous sickle cell anemia presenting to an inner city hospital with bilateral periorbital swelling amid the coronavirus pandemic. Differentials including orbital cellulitis, COVID-MIS-C, orbital inflammatory syndrome, Hoagland sign, and orbital infarction secondary to sickle cell crisis are contrasted. We contrast our case with 12 case reports of orbital infarction in the setting of sickle cell crisis within the past 10 years, highlighting how these presentations, along with commonly reported findings of orbital infarction, compare with our patient. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1462 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1462/963

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 17 1 2023 01 16 9 17 EN Shahram Shojaei Bistoon Hospital, Kermanshah, Iran Mozaffar Aznab Department of Internal Medicine, Talaghani Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran Amirmasoud Rahimi Kermanshah University of Medical Sciences, Kermanshah, Iran Seyed Mojtaba Ahmadi Department of Clinical Psychology School of Medicine, Kermanshah University of Medical Science, Kermanshah, Iran Kumars Eslampia Department of Surgery, Bistoon Hospital, Kermanshah, Iran Arash Golpazir Department of Surgery, Cancer Surgery, Kermanshah University of Medical Sciences, Kermanshah, Iran Masoud Iravani Masoud Gastroenterology and Liver Clinic, Tehran, Iran 2020 09 23 2021 05 09 Background: This study aimed to evaluate the significance of tumor lymphocyte infiltration (TIL) and the number of CD8+ T cells in breast cancer and their relationship with the other clinicopathological factors and overall survival (OS) was investigated. Materials and Methods: The studied samples were breast cancer patients (2005-2017) referring to the medical oncology departments for treatment. Pathologic samples of breast cancer patients were evaluated in terms of TIL and positive immunohistochemical staining for CD8 cytotoxic cells. Results: 299 patients were entered into the study, 3 male and 296 female. Their mean follow-up period was 61 months. Statistical findings indicated that lymph involvement is more accompanied by low TIL within the tumor (0.011). Correlations were observed between the estrogen, progesterone receptors, P53 state, and TIL; which were significant by P-value<0.049, P-value=0.024, P-value =0.002, respectively. With any Ki67 value, the number of patients with less than 30% TIL was more considerable than the two other groups with lymphocyte cut-off of 30-50% and more than 50%. Comparison of the OS of patients with positive and negative CD8 cytotoxic lymphocytes in 45 patients with lymphocyte infiltration of equal or more than 40% showed that the OS results were in favor of patients with CD8+ cytotoxic lymphocyte (0.022). Out of 299 patients, 17 died. Conclusion: Our findings showed that in cases of CD8+ cytotoxic lymphocytes in tumors, the OS of the patients will be enhanced which can act as an independent.   https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1432 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1432/958

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 17 1 2023 01 16 18 27 Seyedeh Sahar Mortazavi Farsani Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran Dina Sadeghizadeh Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran Sadegh Babashah Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran Fariba Rad Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran Majid Sadeghizadeh 1) Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran 2) Alborz Nanomed Technology Company, Tehran, Iran 2020 12 31 2021 05 31 Background: Megakaryopoiesis is characterized by progressive polyploidization and the expression of megakaryocytic markers. Numerous transcription factors and physiological signaling pathways regulate this phenomenon. Megakaryocyte differentiation induction in the K562 cell line and hematopoietic stem cells via nanocurcumin drug has been identified in our previous study. K562 cells are typical Chronic Myelogenous Leukemia (CML) cells that are resistant to apoptosis and express the bcr-abl fusion gene. These cells have the potential to differentiate into erythrocytes and megakaryocytes. Curcumin is well known as a component with strong potential to alter NFκB activity in various cells. NFκB pathway regulates various genes such as apoptotic and immune response genes. The aim of the current study is to evaluate the possible role of nanocurcumin in NFκB pathway regulation during the megakaryopoiesis process in the K562 cell line. Materials and Methods: Megakaryocyte markers expression and phenotype alteration of nanocurcumin-treated K562 cells have been detected by flow cytometry and microscopy imaging. The nuclear level of the RelA (p65) subunit of NFκB was determined by western blot test in K562 cells during megakaryopoiesis induction via nanocurcumin treatment at different times. The expression of NFκB target genes including c-MYC, BAX, and NQO1 was also analyzed in nanocurcumin-treated K562 cells by quantitative RT-PCR assay at different times. Results: It was demonstrated that nanocurcumin leads to an increase in NFκB activity transiently during megakaryocyte differentiation, which is followed by a change in the expression of c-MYC, BAX, and NQO1 target genes. Conclusion: The NFκB pathway can be considered a new pathway for inducing megakaryocyte differentiation by nanocurcumin for the purposes of in vitro and in vivo megakaryopoiesis experiments. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1514 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1514/959

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 17 1 2023 01 16 28 38 Carlos Atencia-Flórez Department of Internal Medicine, University of Antioquia School of Medicine, Medellín, Colombia Catalina Quintero-Valencia Laboratorio Integrado de Medicina Especializada – LIME, Medellin (Antioquia), Colombia María Mondragón-Arismendy Laboratorio Integrado de Medicina Especializada – LIME, Medellin (Antioquia), Colombia Andrés Cardona-Arias University of Antioquia School of Medicine, the SURA Healthcare Insurance Company, Medellin (Antioquia), Colombia Carlos Regino-Agamez Department of Internal Medicine, University of Antioquia School of Medicine, Medellín, Colombia Julián Vélez-Urrego San Vicente Foundation University Hospital, Medellin (Antioquia), Colombia 2021 01 08 2021 05 05 Background:  Multiple myeloma is the second most common hematologic malignancy after lymphomas. Few studies have characterized significant and full variables at the time of diagnosis of multiple myeloma in Colombia, and there is no data evaluating patients for follow-up. Materials and Methods:  A retrospective cohort study is presented, describing the clinical, laboratory, cytometric, and cytogenetic characteristics of patients with a de novo diagnosis of multiple myeloma evaluated in a reference hematology laboratory attached to a highly complex hospital in Medellín, Colombia.  We follow them until death as a main outcome. Results:  A total of 170 patients with a de novo diagnosis of multiple myeloma were collected from a database of 421 patients with different monoclonal gammopathies. Mainly, it was found that 50.8% of the patients were men; the median age was 62 years; 65.4% had secretion of the IgG kappa; half of the patients presented International Staging System (ISS) Stage III. The β2 macroglobulin >4 mg/L and creatinine >2 mg/dl were the main variables significantly associated with survival (Hazard Ratio (HR) 2.4 and 2, respectively). Eighty-five percent of patients presented with bone lytic lesion involvement and less than 3% with extramedullary involvement. Conventional Banding Karyotype (CBK) genetic risk assessment yield was poor, compared with although scarce data regarding Cytogenetic risk assessment based on Fluorescence in-situ Hybridization (FISH). Conclusion:  The clinical profile of the patients with a de novo diagnosis of multiple myeloma in our cohort is similar to that described in international studies. The diagnosis of multiple myeloma was documented at younger ages, with more advanced stages, anemia, and a high percentage of bone disease. ISS provides an excellent tool for prognosis purposes. Cytogenetic risk assessment based on FISH should be done for all MM patients from therapeutic implications. We need standardized protocols for bone marrow sample manipulation and processing in order to guarantee good correlation for plasma cells count methods. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1522 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1522/960

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 17 1 2023 01 16 39 Marziyeh Asadizaker Nursing Care Research Center in Chronic Diseases, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran Mojtaba Jahanifar Shahid Chamran University of Ahvaz, Ahvaz, Iran 2019 12 06 2020 03 01 Background: Uncertainty leads to a stressful situation in patients with thalassemia major that can dramatically affect their psychosocial coping ability, treatment process and disease outcomes, and reduce patients' quality of life. As one of the important factors affecting the health of thalassemia patients, understanding the concept of uncertainty is of major importance to health care providers especially nurses as the first line of exposure to these patients. The present study aimed to explore the experiences of uncertainty in patients with thalassemia major. Materials and Methods: The present qualitative study was conducted through in-depth face-to-face semi-structured interviews held with 18 patients with major thalassemia selected through purposive sampling. Interviews continued until saturation of data. All interviews were recorded, transcribed and analyzed with conventional content analysis method of Landman and Graneheim using MAXQDA10 software. Results: Two main themes, including 'living in the shadow of anxiety' and 'coping with uncertainty' emerged from patients’ experiences of illness uncertainty of thalassemia. 'Living in the shadow of anxiety' included four categories of 'fear of complications', 'contradictory views on treatment', 'unknown future' and 'stigma'. 'Coping with uncertainty' included three categories of 'spiritual coping', 'psychosocial coping' and 'knowledge acquisition'. Conclusion: According to the results of this study, uncertainty is a major psychological stress in patients with thalassemia major. Healthcare providers should therefore consider the challenges and concerns faced by patients and, through utilizing appropriate training and communicational practices, plan interventions and strategies to empower patients for coping with uncertainty.   https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1219 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1219/865

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 14 4 2020 10 07 248 256 EN Aysun Senturk Yikilmaz Department of Hematology, Yıldırım Beyazıt University, Ankara 06010, Turkey Sema Akinci Department of Hematology, Ataturk Training And Research Hospital, Ankara 06010, Turkey Sule Bakanay Department of Hematology, Yıldırım Beyazıt University, Ankara 06010, Turkey İmdat Dilek Department of Hematology, Yıldırım Beyazıt University, Ankara 06010, Turkey 2019 12 01 2020 02 25 Background: Complete response (CR) and very good partial response (VGPR) are targeted with pre-ASCT induction regimens in patients by diagnosed multiple myeloma (MM), who are candidates for ASCT. In this study, it was aimed to compare the response and survival evaluations of cases who underwent induction treatment by vincristine-doxorubicin-dexamethasone (VAD) protocol versus bortezomib containing regimens. Materials and Methods: The data of 96 ASCT eligible patients, retrospectively analyzed. P value> 0.05 was considered statistically significant. Results: While 66 cases had received bortezomib containing regimens as induction regimen, 30 cases had received VAD protocol. The total survival was 91.3 (st.s 6) months and 43 (st.s 7.9) months, respectively, when we compared the cases without ASCT and with ASCT (p = 0.001). The OS of patients who underwent ASCT after reaching at least VGPR was longer than the underwent ASCT without reaching VGPR (p=0.019).  Post-ASCT PFS (p=0.717) and OS (p = 0.126) analyzes were performed in 74 cases undergoing ASCT treatment, there was no significant statistical difference when patients with treated by VAD protochol and treated by bortezomib containing regimens as pre-ASCT induction regimens was compared to each other. Conclusion: Whatever the type of induction regimen is, the level of response achieved before ASCT is important. The survival of the myeloma patients are much more influenced with HDT-ASCT as well as post-transplantation strategies to keep the patients in remission. Even though it is outdated, we think that the VAD protocol may be an option in patients who are not responding with the new generation of agents in the following days. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1216 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1216/866

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 14 4 2020 10 07 257 264 Amirhosein Maali 1) Infection Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran 2) Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran 3) Student Research Committee, Babol University of Medical Sciences, Babol, Iran